The COVID Cloud will enable accelerated and more insightful interpretation of COVID-19, leading to increased preparedness for future outbreaks, and identification of potential treatments.
FACIT is pleased to accept the invitation to join the national consortium as Lead Commercialization Advisor.
Reveal™ enables bone and soft tissue differentiation in a single, highly sensitive x-ray exposure.
Since FACIT’s early seed investment in KA Imaging, the company has greatly expanded its IP portfolio, as well as the number of highly skilled jobs it has brought to Ontario.
